BackgroundStudies using novel antiandrogens (NAA) in patients with metastatic castration-resistant prostate cancer (mCRPC) have shown overall survival benefit.
Xiangyu Chen +7 more
doaj +1 more source
It is well known that the role of gut microbiota in drug metabolism, especially in oral difficult absorbable drugs. Understanding the gut microbiota could enable us to understand drugs in new ways.
Adili Keranmu +7 more
doaj +1 more source
Abiraterone acetate (CB 7630; CB7630; JNJ-212082), the 3β-acetate prodrug of abiraterone, is structurally related to ketoconazole and is being developed by Cougar Biotechnology as a hormonal therapy for advanced prostate and breast cancers. As a selective inhibitor of adrenal androgens, it is thought to be a safer product than existing second-line ...
openaire +3 more sources
Role of abiraterone acetate in the management of metastatic prostate cancer [PDF]
Objective. to analyze the clinical, biological and histological profile of patients with prostate cancer and to assess the efficacy and safety of abiraterone acetate. Patients and methods.
Wafa Bechairia
doaj +1 more source
Abiraterone in metastatic prostate cancer without previous chemotherapy [PDF]
Contains fulltext : 118780.pdf (Publisher’s version ) (Open Access)BACKGROUND: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after ...
Suttmann, Henrik +90 more
core +3 more sources
Abiraterone is a selective inhibitor of androgen biosynthesis approved for the treatment of metastatic patients affected by castration-resistant or castration-sensitive prostate cancer.
Michele Iuliani +7 more
doaj +1 more source
CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2 [PDF]
Abiraterone is an inhibitor of CYP17A1 which is used for the treatment of castration resistant prostate cancer. Abiraterone is known to inhibit several drug metabolizing cytochrome P450 enzymes including CYP1A2, CYP2D6, CYP2C8, CYP2C9, CYP2C19, CYP3A4 ...
Brixius-Anderko, Simone +20 more
core +4 more sources
Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database [PDF]
This real‐world study of the Flatiron Health database found that first‐line treatment with abiraterone versus enzalutamide was associated with significantly shorter overall survival, treatment duration, and time to subsequent treatment in patients with chemotherapy‐ and androgen receptor pathway inhibitor‐naïve metastatic castration‐resistant prostate ...
George D +8 more
europepmc +2 more sources
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. [PDF]
BACKGROUND: Standard medical castration reduces muscle mass. We sought to characterize body composition changes in men undergoing maximal androgen suppression with and without exogenous gluocorticoids.
J S de Bono +32 more
core +1 more source
Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling [PDF]
INTRODUCTION: Castration‐resistant prostate cancer (CRPC) remains dependent on androgen receptor (AR) signalling, which is largely driven by conversion of adrenal androgen precursors lasting after castration.
Guido W. Jenster +30 more
core +1 more source

